CCL2 and liver dysplastic nodule: Baricitinib down-regulates urine CCL2 expression with a decreased urine albumin–creatinine ratio (UACR) in type 2 diabetes patients at high risk for progressive DN in a phase 2 randomized controlled clinical trial [70].